About Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)
Rexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company's clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance. RX-3117 is a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers, including pancreatic, bladder, colon and lung cancer. Supinoxin is a small molecule inhibitor of phosphorylation of p68. The Company also has a drug candidate RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, in pre-clinical development. The Company is working on research technologies, including multi-target aimed ligands platform and nano-based drug delivery systems.
Industry, Sector and Symbol:
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Sector: N/A
- Symbol: NYSEAMERICAN:RNN
- Previous Symbol: NYSEMKT:RNN
- CUSIP: N/A
- Web: rexahn.comcms
- Trailing EPS: ($0.93)
- Return on Equity: 44.61%
- Return on Assets: 15.94%
- Outstanding Shares: 31,730,000
Frequently Asked Questions for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)
What is Rexahn Pharmaceuticals' stock symbol?
Rexahn Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "RNN."
How were Rexahn Pharmaceuticals' earnings last quarter?
Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) announced its quarterly earnings data on Monday, August, 8th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.02) by $0.01. View Rexahn Pharmaceuticals' Earnings History.
Where is Rexahn Pharmaceuticals' stock going? Where will Rexahn Pharmaceuticals' stock price be in 2017?
5 equities research analysts have issued twelve-month target prices for Rexahn Pharmaceuticals' shares. Their forecasts range from $13.00 to $19.50. On average, they anticipate Rexahn Pharmaceuticals' share price to reach $16.50 in the next twelve months. View Analyst Ratings for Rexahn Pharmaceuticals.
Are investors shorting Rexahn Pharmaceuticals?
Rexahn Pharmaceuticals saw a increase in short interest in October. As of October 31st, there was short interest totalling 2,106,770 shares, an increase of 28.0% from the October 13th total of 1,645,486 shares. Based on an average daily trading volume, of 673,912 shares, the days-to-cover ratio is presently 3.1 days. Currently, 6.8% of the company's stock are short sold.
Who are some of Rexahn Pharmaceuticals' key competitors?
Some companies that are related to Rexahn Pharmaceuticals include Verastem (VSTM), Conatus Pharmaceuticals (CNAT), ImmuPharma PLC (IMM), ProNAi Therapeutics (SRRA), MaxCyte (MXCT), Ophthotech Corporation (OPHT), Aldeyra Therapeutics (ALDX), Summit Therapeutics PLC (SUMM), Opexa Therapeutics (ACER), Axsome Therapeutics (AXSM), Redhill Biopharma (RDHL), Galmed Pharmaceuticals (GLMD), AcelRx Pharmaceuticals (ACRX), Verona Pharma Plc (VRP), Trevena (TRVN), Zafgen (ZFGN), Gemphire Therapeutics (GEMP) and ProQR Therapeutics N.V. (PRQR).
Who are Rexahn Pharmaceuticals' key executives?
Rexahn Pharmaceuticals' management team includes the folowing people:
- Peter C. Brandt, Independent Chairman of the Board (Age 59)
- Peter D. Suzdak Ph.D., Chief Executive Officer, Director (Age 57)
- Tae Heum Jeong, Chief Financial Officer, Secretary (Age 45)
- Ely Benaim, Chief Medical Officer (Age 55)
- Charles G. Beever, Independent Director (Age 63)
- Mark P. Carthy, Independent Director (Age 55)
- Kwang Soo Cheong Ph.D., Independent Director (Age 55)
- Richard J. Rodgers, Independent Director (Age 50)
Who owns Rexahn Pharmaceuticals stock?
Who bought Rexahn Pharmaceuticals stock? Who is buying Rexahn Pharmaceuticals stock?
How do I buy Rexahn Pharmaceuticals stock?
Shares of Rexahn Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Rexahn Pharmaceuticals' stock price today?
One share of Rexahn Pharmaceuticals stock can currently be purchased for approximately $2.11.
How big of a company is Rexahn Pharmaceuticals?
Rexahn Pharmaceuticals has a market capitalization of $64.12 million.
How can I contact Rexahn Pharmaceuticals?
Rexahn Pharmaceuticals' mailing address is 15245 Shady Grove Rd Ste 455, ROCKVILLE, MD 20850-7203, United States. The company can be reached via phone at +1-240-2685300.
MarketBeat Community Rating for Rexahn Pharmaceuticals (NYSEAMERICAN RNN)MarketBeat's community ratings are surveys of what our community members think about Rexahn Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 5 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$16.50|
Consensus Price Target History for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)
Analysts' Ratings History for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)
(Data available from 11/21/2015 forward)
|11/6/2017||HC Wainwright||Reiterated Rating||Buy||$19.50|
|10/6/2017||Seaport Global Securities||Reiterated Rating||Buy||$13.00|
|8/7/2017||Ifs Securities||Reiterated Rating||Outperform|
|6/9/2017||Rodman & Renshaw||Reiterated Rating||Buy||$19.50|
|6/1/2017||FBR & Co||Reiterated Rating||Outperform||$30.00 -> $14.00|
|2/29/2016||Roth Capital||Reiterated Rating||Buy||$1.75|
Earnings History and Estimates Chart for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)
Earnings History by Quarter for Rexahn Pharmaceuticals (NYSEAMERICAN RNN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Rexahn Pharmaceuticals (NYSEAMERICAN RNN)
Insider Trades by Quarter for Rexahn Pharmaceuticals (NYSEAMERICAN RNN)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|4/10/2017||Chang Ho Ahn||Director||Sell||250,000||$0.70||$175,000.00|| |
|1/12/2015||Chang Ho Ahn||Director||Sell||314,656||$0.91||$286,336.96|| |
|1/12/2015||Tae Heum Jeong||CFO||Sell||317,272||$0.91||$288,717.52|| |
|6/12/2014||Chang Ho Ahn||Director||Sell||136,193||$0.99||$134,831.07|| |
|9/9/2013||Tae Heum Jeong||CFO||Sell||71,139||$0.46||$32,723.94|| |
Latest Headlines for Rexahn Pharmaceuticals (NYSEAMERICAN RNN)
No headlines for this company have been tracked by MarketBeat.com
Rexahn Pharmaceuticals (NYSEAMERICAN RNN) Chart for Tuesday, November, 21, 2017